CRC Research Update — July 01, 2026
Today's colorectal cancer research highlights
The CRC Digest
Curated CRC research — accessible, accurate, actionable
Wednesday, July 01, 2026
2 min readIMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
Metabolic pathway drives cetuximab resistance in metastatic colorectal cancer
Researchers found that cetuximab treatment stabilizes the enzyme GDH1, leading to accumulation of α-ketoglutarate that remodels the tumor immune microenvironment and drives resistance; depleting GDH1 sensitized cancer cells to cetuximab in preclinical models. (Cell Death Dis)
-
Computer-aided detection improves colonoscopy adenoma detection across expertise levels
A retrospective study of 724 matched patients found that computer-aided detection (CADe) systems improved adenoma and polyp detection rates during colonoscopy for both expert endoscopists and trainees under diverse clinical conditions. (In Vivo)
-
H. pylori infection linked to increased colorectal cancer risk in two large trials
Analysis of two randomized trials in China involving over 180,000 participants found that H. pylori infection was associated with increased colorectal cancer risk, with the association modified by genetic predisposition. (Gut)
-
Multi-omics deep learning model predicts anti-EGFR therapy response in liver metastases
A multi-center study developed a deep learning framework integrating multi-omics data to predict which RAS wild-type colorectal cancer liver metastases patients will benefit from cetuximab therapy, addressing primary resistance challenges. (Curr Cancer Drug Targets)
Research continues to advance our understanding of treatment resistance, early detection, and supportive care strategies for the colorectal cancer community.
The CRC Digest
Research intelligence for the colorectal cancer community
Get CRC research intelligence delivered weekly — free.
SubscribeBrowse by Topic
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.